| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.26(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,579 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
91,318 |
237,059 |
410,079 |
888,401 |
| Total Sell Value |
$6,319,460 |
$16,812,843 |
$22,688,654 |
$44,103,545 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
4 |
16 |
36 |
82 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kaye Edward M. Md |
Director |
– • – |
2021-12-23 |
4 |
AS |
$45.00 |
$675,000 |
D/D |
(15,000) |
6,765 |
|
-8% |
|
| Kaye Edward M. Md |
Director |
– • – |
2021-12-23 |
4 |
OE |
$7.61 |
$114,150 |
D/D |
15,000 |
21,765 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-12-09 |
4 |
AS |
$36.49 |
$1,064,288 |
D/D |
(29,166) |
149,314 |
|
4% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-12-09 |
4 |
OE |
$6.30 |
$183,746 |
D/D |
29,166 |
172,053 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2021-11-19 |
4 |
S |
$41.21 |
$1,196,275 |
D/D |
(29,032) |
6,765 |
|
2% |
|
| Smith Sandford D |
Director |
– • – |
2021-11-19 |
4 |
OE |
$9.45 |
$382,247 |
D/D |
29,032 |
10,797 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2021-11-12 |
4 |
AS |
$39.63 |
$164,172 |
D/D |
(4,143) |
360,063 |
|
-6% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-11-12 |
4 |
OE |
$6.00 |
$24,858 |
D/D |
4,143 |
364,206 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-11-11 |
4 |
AS |
$39.56 |
$79,120 |
D/D |
(2,000) |
148,878 |
|
-8% |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-11-09 |
4 |
S |
$41.76 |
$1,879,209 |
D/D |
(45,000) |
138,704 |
|
11% |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-11-09 |
4 |
OE |
$9.65 |
$434,250 |
D/D |
45,000 |
159,185 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2021-11-08 |
4 |
S |
$41.33 |
$1,094,023 |
D/D |
(26,468) |
28,932 |
|
11% |
|
| Gage L Patrick |
Director |
– • – |
2021-11-08 |
4 |
OE |
$4.02 |
$112,400 |
D/D |
26,468 |
33,098 |
|
- |
|
| Parshall B Lynne |
Director |
– • – |
2021-11-05 |
4 |
AS |
$40.00 |
$1,239,840 |
D/D |
(30,996) |
5,000 |
|
-13% |
|
| Parshall B Lynne |
Director |
– • – |
2021-11-05 |
4 |
OE |
$6.78 |
$382,381 |
D/D |
30,996 |
7,798 |
|
- |
|
| Henderson John T |
Director |
– • – |
2021-11-05 |
4 |
AS |
$40.00 |
$340,120 |
D/D |
(8,503) |
13,255 |
|
-13% |
|
| Henderson John T |
Director |
– • – |
2021-11-05 |
4 |
OE |
$5.88 |
$49,998 |
D/D |
8,503 |
21,758 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-11-01 |
4 |
AS |
$34.89 |
$872,240 |
D/D |
(25,000) |
138,704 |
|
-1% |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-11-01 |
4 |
OE |
$6.00 |
$150,000 |
D/D |
25,000 |
157,029 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2021-10-29 |
4 |
AS |
$35.80 |
$178,997 |
D/D |
(5,000) |
360,063 |
|
-1% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-10-29 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
365,063 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2021-10-19 |
4 |
AS |
$35.73 |
$1,275,186 |
D/D |
(35,687) |
53,064 |
|
7% |
|
| Parshall B Lynne |
Director |
– • – |
2021-10-19 |
4 |
AS |
$35.73 |
$369,207 |
D/D |
(10,332) |
5,000 |
|
7% |
|
| Parshall B Lynne |
Director |
– • – |
2021-10-19 |
4 |
OE |
$6.60 |
$68,671 |
D/D |
10,332 |
13,333 |
|
- |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2021-10-19 |
4 |
AS |
$35.74 |
$713,970 |
D/D |
(19,979) |
50,850 |
|
7% |
|
1103 Records found
|
|
Page 14 of 45 |
|
|
0.91 (1.51%) 
